A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
This clinical trial is a Phase 3, randomized, double-blind, placebo-controlled, multicenter
study evaluating acalabrutinib plus BR compared with placebo plus BR in subjects with
previously untreated MCL.
Approximately 546 subjects meeting the eligibility criteria for the study will be randomized